Evaluation of anti-inflammatory and analgesic activity of a novel rigid 3, 4-dihydroxy chalcone in mice.
There have been many reports indicating the analgesic and anti-inflammatory effects of 3,4-dihydroxychalcones. We have designed and synthesized a rigid 3,4-dihydroxychalcone (RDHC) as a possible drug effecting inflammation and nociception. The analgesic and anti-inflammatory effects were evaluated by formalin and hot-plate tests, respectively. The results showed that RDHC induced significant antinociceptive and anti-inflammatory effects (P < 0.01). Maximum analgesia (63.7%) was observed at 37.5 mg/kg in the first phase of the formalin test. The effect of RDHC was higher in the chronic phase (inflammation phase) of the formalin test (86.4%, P < 0.01). In addition, a significant analgesia (maximum possible effect; MPE = 30.1%) was observed in the hot plate test 45 min after injection of 37.5 mg/kg RDHC (P < 0.01). As a result of our findings, this new RDHC could be suggested for further pharmacological studies.
Heidari
M R
MR
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Pharmaceutics and Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran. heidarimr@kmu.ac.ir
Foroumadi
A
A
Amirabadi
A
A
Samzadeh-Kermani
A
A
Azimzadeh
B S
BS
Eskandarizadeh
A
A
D000700:Analgesics / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D002599:Chalcone / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005557:Formaldehyde; D006358:Hot Temperature / Q000009:adverse effects; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D051379:Mice; D015394:Molecular Structure; D009020:Morphine / Q000032:analysis / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010146:Pain / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D010147:Pain Measurement / Q000379:methods
C543700:3-(3,4-dihydroxybenzylidene)-7-methoxy-2,3-dihydrochromen-4-one; D000700:Analgesics; D000701:Analgesics, Opioid; D000893:Anti-Inflammatory Agents; D009292:Narcotic Antagonists; D005557:Formaldehyde; D009270:Naloxone; D002599:Chalcone; D009020:Morphine; D001241:Aspirin